Latest News and Press Releases

FDA approves Sanofi's Tzield as first disease-modifying therapy for children 8-17 with stage 3 type 1 diabetes, delaying insulin decline based on PROTECT

La FDA approuve le Tzield de Sanofi comme première thérapie modificatrice pour enfants 8-17 ans atteints de diabète type 1 stade 3, retardant le déclin ins

embecta and Direct Relief announce a significant expansion of their partnership to increase access to diabetes care for communities worldwide

The FITTER Forward Expert Recommendations are an updated set of global best practices for insulin injection technique and education.

embecta will be joined by diabetes advocacy groups to ring the Nasdaq Closing Bell today in recognition of National Diabetes Awareness Month in November.

GERMANTOWN, Md., Aug. 30, 2022 (GLOBE NEWSWIRE) -- The regenerative medicine company Seraxis Inc. today announced the appointment of Paul Strumph, M.D. as Chief Medical Officer. Dr. Strumph is an...

OTTAWA, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Nearly one-third of Ontario parents aren’t confident that school staff can keep their kids with type 1 diabetes safe, according to new data released today...

NEW YORK, NY--(Marketwired - February 08, 2016) - Johnson & Johnson (J&J), like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1...

NEW YORK, April 24, 2013 (GLOBE NEWSWIRE) -- The Helmsley Charitable Trust today announces that it has approved new grants totaling more than $3.9 million to 29 camp organizations to fund nearly 7,800...